Summary
Summary: Mast cells (MCs) are tissue-resident immune cells that are best known for mediating IgE/FcεRI-mediated hypersensitivity and atopic disorders. However, recent excitement in MC research has been the realization that a diverse group of cationic amphipathic peptides and FDA-approved drugs activate human MCs via a novel G protein coupled receptor (GPCR) known as MRGPRX2 (mouse counterpart, MrgprB2). This receptor is implicated in host defense, immediate drug hypersensitivity reactions (IDHRs), neurogenic inflammation/pain and a variety of cutaneous disorders. Not surprisingly, there is an
